Table 3

Adverse events of all participants.

Adverse events (n)MTX (n=69)TwHF (n=69)MTX+TwHF (n=69)Total events (n=207)
All43 (62.3)32 (46.4)34 (49.3)109 (52.7)
Gastrointestinal, n (%)30 (43.5)20 (29.0)24 (34.8)74 (35.7)
Nausea761023
Vomiting1214
Regurgitation1023
Loss of appetite101617
Diarrhoea3216
Abdominal distention2237
Abdominal discomfort117826
ALT elevation114621
GGT elevation1001
Infection, n (%)10 (14.5)3 (4.3)7 (10.1)20 (9.7)
Upper respiratory tract infection3104
Pneumonia1023
Urinary tract infection2002
Vaginitis2002
Leucocytopenia42511
Skin and mucous event, n (%)14 (20.3)7 (10.1)14 (20.3)35 (16.9)
Dry skin1113
Rash2259
Baldness32510
Skin pigmentation1225
Ulcer81615
Irregular menstruation, n (%)*3 (5.1)7 (12.5)5 (9.1)15 (8.8)
Other adverse events, n (%)16 (23.2)5 (7.2)13 (18.8)34 (16.4)
Fatigue5218
Weight loss3014
Anemia71614
Palpitations3014
Haematuria1001
Peripheral oedema0123
Headache3126
  • *The percentages of irregular menstruation were based on the total number of female patients in each group.

  • ALT, alanine aminotransferase; GGT, γ-glutamyl transferase; MTX, methotrexate; TwHF, Tripterygium wilfordii Hook F.